Figure 1. Epigenomic landscape modulation as adaptation to MEK inhibition. Following trametinib treatment, triple negative breast cancer cells adapt by seeding the formation of new BRD4-rich enhancers to induce transcription of proximal receptor tyrosine kinase genes and other genes in growth/survival promotion pathways leading to drug resistance. BET bromodomain inhibition attenuates this response in combination with MEK inhibition.
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
